Skip to menu Skip to content Skip to footer

Protease Activated Receptor 2 : A New Drug Target For Inflammatory Diseases and Cancer (2009-2012)

Abstract

A new class of proteins (Protease Activated Receptors) has been found on the surfaces of many different types of cells. They are believed to be natural sensors that respond to traces of degradative enzymes called proteases. This project will create and evaluate new drugs for one of these receptors thought to regulate inflammatory diseases (e.g. arthritis, inflammatory bowel disease, asthma, pancreatitis) and cancers, while providing a better understanding of a new mechanism of immune defence.

Experts

Professor David Fairlie

Centre Director of The Centre for C
Centre for Chemistry and Drug Discovery
Institute for Molecular Bioscience
Affiliate of ARC COE for Innovation
ARC Centre of Excellence for Innovations in Peptide and Protein Science
Institute for Molecular Bioscience
Centre Director of Institute for Mo
Institute for Molecular Bioscience
NHMRC Leadership Fellow and Group L
Institute for Molecular Bioscience
David Fairlie
David Fairlie

Associate Professor David Vesey

Honorary Associate Professor
PA Southside Clinical Unit
Faculty of Medicine
David Vesey
David Vesey